Anthony J. Di Pasqua

Dr. Anthony J. Di Pasqua

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Materials
Verified
Journal Article
Open access
PDF file
MSMengwei Sun
Mengwei Sun
OOOsitomiwa O. Osipitan
Ositomiwa O. Osipitan
ESEwa Sulicz
Ewa Sulicz
APAnthony J. Di Pasqua
Anthony J. Di Pasqua
The pain caused by lidocaine injections into the face prior to facial plastic surgeries intended to remove growths or tumorous lesions has been reported by many patients to be the worst part of these procedures. However, the lidocaine gels and creams currently on the market do not deliver an equal or better local anesthetic effect to replace these injections. To develop an alternative to the painful local anesthetic injection, we prepared ultraflexible liposomes using soy phosphatidylcholine, lidocaine, and different amounts of sodium cholate, a surfactant. The prepared ultraflexible liposomes (UFLs) were examined for particle size, zeta potential, cytotoxicity, and in vitro release. By using a carbomer as a gelling agent, the prepared UFL lidocaine gels were evaluated for their penetration ability in a Franz diffusion cell, using Strat-M membranes. The formulation achieving the highest amount of penetrated lidocaine was chosen for further pH, viscosity, and stability tests. The local anesthetic efficacy of the formulation was investigated by an in vivo tail-flick test in rats. Our findings suggested that this topical gel formulated with ultraflexible liposomal lidocaine has enhanced skin permeation ability, as well as an improved local analgesic effect from the lidocaine.

28 September 2024 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
ADAnna H. Dlott
Anna H. Dlott
SSSara A. Spencer
Sara A. Spencer
APAnthony J. Di Pasqua
Anthony J. Di Pasqua
This review examines the pharmacology, efficacy and safety, dosage and administration, and place in therapy of the combination of 5-fluorouracil (5-FU) and calcipotriol for the treatment of actinic keratosis. Currently, 5% 5-FU topical cream is approved for actinic keratosis treatment, while calcipotriol is indicated for plaque psoriasis in adults. The typical administration of 5-FU involves topical application twice daily for up to 4 weeks, whereas calcipotriol is applied in a thin layer once or twice daily as directed by a physician. Adverse effects of 5-FU are primarily localized, including skin irritation, ulceration, pruritus, erythema, crusting, and eczematous reactions due to minimal systemic absorption. Calcipotriol may cause burning, itching, and skin irritation. This review details clinical trials that investigate the innovative approach of combining topical 5-FU with calcipotriol for actinic keratosis treatment, highlighting the significant outcomes. Notably, the clinical trials indicate that all participants experienced either a reduction in lesion size or complete lesion clearance, with minimal adverse effects impacting treatment success. The combination of 5-FU and calcipotriol effectively treats actinic keratosis by enhancing the immune response and targeting cell overgrowth, while reducing local site reactions and the lengthy treatment time often associated with existing therapies.

14 October 2022 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
OOOsitomiwa O. Osipitan
Ositomiwa O. Osipitan
MSMengwei Sun
Mengwei Sun
HGHeather Gordish-Dressman
Heather Gordish-Dressman
RWRichard Wendt
Richard Wendt
MWMary Wight-Carter
Mary Wight-Carter
APAnthony J. Di Pasqua
Anthony J. Di Pasqua

29 January 2026 in Materials
Verified
Journal Article
Open access
PDF file
DSDevansh Sharma
Devansh Sharma
SGShantanu Gopal Gaurkhede
Shantanu Gopal Gaurkhede
JDJia Deng
Jia Deng
APAnthony J. Di Pasqua
Anthony J. Di Pasqua
Conventional gelatin capsules deliver a rapid drug release in the stomach, which is suboptimal for therapies requiring controlled and delayed release, emphasizing the need for customizable drug delivery systems for precision medicine. This study’s objective was to optimize 3D-printed capsule shells formulated with pH-responsive polymer blends—hydroxypropyl methylcellulose acetate succinate (HPMC-AS), PEG-4000, and PVA—to achieve controlled and sustained drug release, comparing profiles against a commercial enteric capsule. Capsule shells were produced via fused filament fabrication (FFF) at two ratios (80:15:5 and 70:20:10), filled with acetaminophen (250 mg), and tested using a two-stage dissolution method (simulated gastric fluid (SGF) for 2 h followed by simulated intestinal fluid (SIF) for 4–5 h). Results showed negligible drug release in SGF (≤5%) for both printed and commercial capsules. However, in SIF, the commercial capsule released its payload rapidly (>80% within 15 min), while the 3D-printed capsules achieved a prolonged, gradual release. The higher HPMC-AS content significantly extended the release duration. All capsules met the pharmacopeial weight uniformity criteria. In conclusion, the 3D-printed shells provided a controllable, sustained drug release profile, underscoring 3D printing’s potential to create tunable, patient-specific dosage forms.

29 August 2025
Verified
Book Chapter
Closed access
PDF file
MSMengwei Sun
Mengwei Sun
APAnthony J. Di Pasqua
Anthony J. Di Pasqua

26 November 2025 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
SDShivani A. Dave
Shivani A. Dave
AKAdam B. Keeton
Adam B. Keeton
GPGary Piazza
Gary Piazza
APAnthony J. Di Pasqua
Anthony J. Di Pasqua